Biosimilars

Brain Cancer

HER2+ Breast Cancer

Breast Cancer

CAR T-cell Therapy

COVID-19

Disparities in Cancer Care

Colorectal Cancer

Gastric Cancer

Hepatocellular Carcinoma

Pancreatic Cancer

Gastrointestinal Cancer

Prostate Cancer

Urothelial Cancer

Genitourinary Cancers

Global Oncology

Ovarian Cancer

Gynecologic Oncology

Head & Neck Cancers

Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Non-Hodgkin Lymphoma

Hematologic Oncology

Immuno-Oncology

Lung Cancer

Melanoma & Skin Cancer

Oncology Business Management

Pediatric Oncology

Precision Medicine in Oncology®

Sarcomas

Supportive Care

Experts highlight the top presentations to watch for at the 2025 Genitourinary Cancers Symposium. 

Oncology Experts Preview Top Abstracts From 2025 ASCO GU

Neeta Somaiah, MD, discusses ongoing research with novel agents that have emerged and those that could soon emerge in the sarcoma treatment paradigm. 

Dr Somaiah on Ongoing Research With Novel Agents in Sarcomas

Omid Hamid, MD, provides insight on the potential role of cancer vaccines in melanoma.

Dr Hamid on the Potential for Cancer Vaccines in Melanoma

Marlana M. Orloff, MD, discusses optimal therapeutic approaches for patients with uveal melanoma that is rapidly progressing.

Dr Orloff on Treatment Strategies for Rapidly Progressing Uveal Melanoma

News

OncClub

All Oncology News

Media

Insights

MedNews Week

OncChats

OncLive News Network®

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

CME/CE

Scientific Interchanges

State of the Science Summit / IPC

National Fellows Forum

Webinars

Partners

Publications

Resources

Interactive Tools

Biomarker Consortium

Subscribe

 
Kristi Rosa joined MJH Life Sciences in 2016 and has since held several positions within the company. She helped launch the rapidly growing infectious disease news resource 

. Prior to working at the company, she served as lead copywriter and marketing coordinator at The Strand Theater. Email: krosa@onclive.com

Articles

 in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com

Kyle Doherty joined MJH Life Sciences in 2021 and is the lead editor for 

as well as news and conference updates for OncLive.com. Email: kdoherty@mjhlifesciences.com

Megan Hollasch joined MJH Life Sciences in 2022 following graduation from the University of Massachusetts Amherst with majors in Communication and English, and a specialization in Literature as History. She produces and edits original content for the print publication 

, aiding in all aspects of the publication process, as well as content for OncLive.com.

Daniel J. DeAngelo, MD, PhD, details how the split dosing of obe-cel yields reduced toxicities and makes it a unique CAR T-cell therapy for relapsed/refractory ALL.

Obe-Cel Represents a Unique CAR T-Cell Therapy for Patients with Relapsed/Refractory ALL

Ritu Salani, MD, MBA, details considerations for cervical cancer treatment as new approvals, research, and modalities affect several settings. 

Open Surgery Approaches and Sequencing Considerations Represent Core Parts of the Shifting Cervical Cancer Field

Short-course, higher dose vaginal brachytherapy for endometrial cancer had similar effectiveness to more frequent, lower dose sessions.

Short-Course Radiation Therapy Effective for Endometrial Cancer Patients

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Advertise

About OncLive

Editorial Board

MJH Life Sciences brands

Contact Us

Privacy

Terms & Conditions

Do Not Sell My Information

OncLive - Clinical Oncology News, Cancer Expert Insights

Facebook

LinkedIn

Youtube

Spotlight

In-person and virtual events just for HCPs

CME Opportunities

Specialty

OncLive Peer Exchange®

Evolving Treatment Paradigms for Renal Cell Carcinoma

Videos

Newly Diagnosed Metastatic Renal Cell Carcinoma

mRCC Patient Selection for Ipilimumab/Nivolumab

mRCC: Cytoreductive Nephrectomy in the Modern Era

Risk Stratification for Metastatic Renal Cell Carcinoma

Selecting Immunotherapy versus VEGF TKI for mRCC

Deferred Therapy for Favorable-Risk mRCC Patients

VEGF TKI + Immunotherapy Combinations for mRCC

Sunitinib 4/2 vs 2/1 Schedule for Patients with mRCC

Disease Progression in Patients with Metastatic RCC

Sequencing Approaches in Metastatic Renal Cell Carcinoma 

Considerations for Using Adjuvant Therapy in mRCC

Evolving Treatment Landscape of Renal Cell Carcinoma

Evolving Treatment Paradigms for Renal Cell Carcinoma

Latest Conference Coverage